Evaluate the PK of LY03010 Process 1 and Process 2 Drug Product vs INVEGA SUSTENNA After Intramuscular Injection in Schizophrenia Patients

Schizophrenia Patients Clinical Trial

Official title:

A Randomized, Open-Label, Parallel, Single-Dose Study to Evaluate the Pharmacokinetic Characteristics of LY03010 Process 1 and Process 2 Drug Product Versus INVEGA SUSTENNA After Intramuscular Injection in Schizophrenia Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04572685
• Other study ID #: LY03010/CT-USA-102
• Status: Completed
• Phase: Phase 1
• Start date: January 22, 2020
• Est. completion date: August 20, 2020

Study information

• Verified date: November 2020
• Source: Luye Pharma Group Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objectives of the study are to characterize the pharmacokinetic (PK) profiles of paliperidone in LY03010 P1 and P2 following a single IM injection in schizophrenia patients and to compare the PK of LY03010 P1 and P2 with that of INVEGA SUSTENNA® following a single IM injection of 156 mg dosage level.

Description:

This is a randomized, open-label, parallel-group, single-dose study. Patients will undergo screening evaluations to determine eligibility within 28 days prior to study drug administration. About 36 patients will be randomized in a 1:1:1 ratio to 1 of 3 treatment groups. Patients will be admitted to the clinical facility the day before dosing (Day 0) and will be receiving an IM injection of study drug and completing the assigned study activity including PK sample collection on Day 1. Patients will be discharged on Day 2 after PK collection. All patients will return to the clinical site at designated study days for PK sample collections and assigned clinical procedures. End of study evaluation will be completed on Day 120. Pharmacokinetics of the study medication will be assessed as primary outcome. Participants' safety will be monitored throughout the study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 36
• Est. completion date: August 20, 2020
• Est. primary completion date: June 26, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Male or female =18 to =65 years of age who meets diagnostic criteria for schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-V) for at least 1 year before screening
• Have been on a stable dose of oral antipsychotic medication(s) other than risperidone, paliperidone, clozapine, ziprasidone, or thioridazine for at least 4 weeks prior to screening
• Clinically stable based on clinical assessments and a Positive and Negative Syndrome Scale (PANSS) total score =70 as well as a PANSS HATE (hostility, anxiety, tension and excitement) subtotal score <16 at screening
• Clinical Global Impression-Severity (CGI-S) score of 1 to 4, inclusive
• Body mass index (BMI) =17.0 and =37kg/m2; body weight =50 kg
• Creatinine level within the normal range
• All female patients (childbearing potential and non-childbearing potential) must have a negative pregnancy test result at both screening and baseline.
• Sexually active fertile male patients must be willing to use acceptable contraception methods (such as double barrier methods of a combination of male condom with either cap, diaphragm or sponge with spermicide) from study drug dosing, throughout the study, and for another 80 days after the EOT visit (or at least 200 days after the dose, whichever is longer) if their partners are women of childbearing potential.

Exclusion Criteria:

• Primary and active DSM-V Axis I diagnosis other than schizophrenia
• Patients who meet DSM-V criteria for substance abuse (moderate or severe) with the exception of caffeine or nicotine in the past 6 months prior to screening, or test positive for barbiturate or alcohol at screening or baseline
• Patients who received any of following treatment:
• Use of oral risperidone or paliperidone within 2 weeks before screening.
• Use of clozapine, thioridazine or ziprasidone within 4 weeks before screening.
• Use of 2-week depot formulation of risperidone within 3 months, 1-month depot formulation of risperidone or 9-hydroxy risperidone (INVEGA SUSTENNA) within 1 year,
• Known or suspected hypersensitivity or intolerance of risperidone, paliperidone, or any of their excipients (oral risperidone tolerability test should be completed during the screening period
• QTcF interval greater than 450 msec for males and 470 msec for females or a prior history or presence of circumstances
• Medical history (within 2 years) of clinically significant, gastrointestinal, cardiovascular, cerebrovascular, musculoskeletal, endocrine, hematologic, renal, hepatic, bronchopulmonary, neurologic, immunologic disorders, or drug hypersensitivity which, in the judgement of the Investigator, would interfere with the patient's ability to participate in the study
• History of dementia-related psychosis or Parkinson's Disease

Related Conditions & MeSH terms

• Schizophrenia
• Schizophrenia Patients

Intervention

Drug:
• Paliperidone Palmitate
A long acting extended release injectable suspension intended for monthly intramuscular administration

Locations

Country	Name	City	State
United States	Hassman Research Institute	Berlin	New Jersey

Sponsors (3)

Lead Sponsor	Collaborator
Luye Pharma Group Ltd.	Alliance for Clinical Trials in Oncology, Evolution Research Group

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To characterize the Maximum Plasma Concentration [Cmax]of LY03010 P1, P2 and INVEGA SUSTENNA following a single IM injection of 156 mg dosage level in schizophrenia patients	The Cmax of LY03010 P1, P2 and INVEGA SUSTENNA will be measured	120-Day
Primary	To characterize Area under the plasma concentration versus time curve (AUC) of LY03010 P1 and P2 and INVEGA SUSTENNA following a single IM injection of 156 mg dosage level in schizophrenia patients.	The AUCs of LY03010 P1, P2 and INVEGA SUSTENNA will be evaluated	120-Day
Primary	To compare the Cmax of LY03010 P1 and P2 with the Cmax of INVEGA SUSTENNA	The relative bioavailability of LY03010 P1 and P2 to Invega Sustenna will be assessed	120-Day
Primary	To compare the AUCs of LY03010 P1 and P2 with the AUCs of INVEGA SUSTENNA	The relative bioavailability of LY03010 P1 and P2 to Invega Sustenna will be assessed	120-Day
Secondary	To evaluate the safety and tolerability of tested drugs. Safety assessments include Incidence of adverse events.	AE will be monitored throughout of the study course	120 day
Secondary	To evaluate the safety of the tested drugs-- Incident of abnormal vital sign	Vital Sign will be measured on Day1 ,2, 4, 6, 8,10,12,15, 17,19, 22 ,29, 64, 92 and Day 120	120 Day
Secondary	To evaluate the safety of the tested drugs-- Incident of abnormal ECG Findings	12-Lead ECG will be measured on Day 0, 29, 64, 92 and Day 120	120 Day
Secondary	To evaluate any abnormal movement symptoms measured by Abnormal Involuntary Movement Scale (AIMS). AIMS measures movement of each part of body muscle with score range of 0-4, 0 means None and 4 means Severe.	AIMS will be measured on Day 0, 15, 29, 64, 92 and Day 120	120-Day
Secondary	To evaluate any abnormal movement symptoms measured by Barnes Akathisia Rating Scale (BARS). BARS is a rating scale for drug-induced akathisia with a range of 0-14; 0 means Normal and 14 means Severe.	BARS will be measured on Day 0, 15, 29, 64, 92 and Day 120	120-Day
Secondary	To evaluate any suicidal attempts measured by Columbia Suicide Severity Rating Scale ( C-SRRS). C-SRRS measures the suicidal intensity of ideation and attempt with score of 1-5; 1 means the least severe and 5 means the most severe.	C-SSRS will be measured on Day 0, 29, 64, 92 and Day 120	120-Day